N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl) sulfonyl-2-hydroxy-2-methyl-propanamide

Absorption
Well absorbed. T max is 31.3 h (active isomer). C max is 0.77 mcg/mL (active isomer).

Distribution
96% protein bound.

Metabolism
Undergoes stereospecific metabolism. The S-isomer (inactive) is metabolized by glucuronidation. The R-isomer (active) undergoes glucuronidation but is predominantly oxidized to an inactive metabolite.

Elimination
Eliminated in urine and feces; t ½ is 5.8 days (active isomer).

Special Populations
Hepatic Function Impairment
The t ½ of the R-isomer is increased about 76% in patients with severe liver disease. No dosage adjustment is necessary.

Warfarin
Prothrombin time may increase when bicalutamide is initiated in patients stabilized on chronic warfarin therapy.